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Abstract
Objective: Testosterone has a spectrum of effects on the male organism. This review attempts to
determine, from published studies, the time-course of the effects induced by testosterone replacement
therapy from their ﬁrst manifestation until maximum effects are attained.
Design: Literature data on testosterone replacement.
Results: Effects on sexual interest appear after 3 weeks plateauing at 6 weeks, with no further
increments expected beyond. Changes in erections/ejaculations may require up to 6 months. Effects on
quality of life manifest within 3–4 weeks, but maximum beneﬁts take longer. Effects on depressive
mood become detectable after 3–6weeks with a maximum after 18–30 weeks. Effects on erythropoiesis
are evident at 3 months, peaking at 9–12 months. Prostate-speciﬁc antigen and volume rise,
marginally, plateauing at 12 months; further increase should be related to aging rather than therapy.
Effects on lipids appear after 4 weeks, maximal after 6–12 months. Insulin sensitivity may improve
within fewdays, but effects on glycemic control become evident onlyafter 3–12 months. Changesin fat
mass, lean body mass, and muscle strength occur within 12–16 weeks, stabilize at 6–12 months, but
can marginallycontinue over years. Effects on inﬂammation occur within 3–12 weeks. Effects on bone
are detectable already after 6 months while continuing at least for 3 years.
Conclusion: The time-course of the spectrum of effects of testosterone shows considerable variation,
probably related to pharmacodynamics of the testosterone preparation. Genomic and non-genomic
effects, androgen receptor polymorphism and intracellular steroid metabolism further contribute to
such diversity.
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Introduction
Treatment of hypogonadal men with testosterone is
rewarding, for the patients as well as the physician. The
patientexperiences,tohissatisfaction,profoundchanges
in his physical appearance and his mental makeup. The
attending physician observes the changes the patient
undergoes and rarely fails to be fascinated by the
multitude of functions testosterone appears to have in
the process of masculinization in the broadest sense (1).
While the effects of testosterone have been described
in detail, relatively little attention has been given to the
time these effects take to occur and achieve a full
expression. This seems relevant. To the attending
physician, monitoring the effects of administration of
testosterone will be facilitated when it is known when
certain effects can and should be expected. Patients like
to receive information when the effects will set in. If
patients have not been exposed to testosterone at the
usual time of puberty, they must be prepared and
counseled about the emergence of sexual thoughts and
dreams, an increase in erections and seminal emissions,
and when to expect them. Furthermore, this infor-
mation is relevant for the design of clinical trials on
testosterone replacement therapy. It is important to
have information when an effect can be expected and
when its maximum has been attained.
Methodological search
Data to compile a time-course for the diverse actions of
testosterone are not easily available. They originate
from studies analyzing the effects of testosterone
administration to hypogonadal men or, alternatively,
from studies on androgen deprivation. The main source
of information will be the former category. Nearly all of
these studies were not speciﬁcally designed to address
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nevertheless a number of controlled studies with
different design and scheduled follow-up, allow a
reasonable estimation.
Studies were identiﬁed by a computerized search of
MEDLINE, the Cochrane Library, EMBASE, and Current
Contents for the past 35 years (1976–2011), by
searching the bibliographies of all retrieved articles and
examining references of review articles found during the
search to identify additional studies. The search was
focused on trials published later than 1975, because at
that time testosterone assays became widespread and
morereliable.Thecomputerizeddatabasesearchusedthe
following keywords and MESH terms in any combination
of: ‘fat mass’, ‘lean mass/muscle/strength’, ‘body compo-
sition’, ‘bone density/markers’, ‘serum lipids/cholesterol’,
‘diabetes’, ‘glycemia’, ‘insulin resistance’, ‘inﬂammatory
markers’, ‘endothelial function’, ‘sexual function’, ‘impo-
tence/erectile/dysfunction’, ‘libido’, ‘mood’, ‘depression’,
‘cognitive function’, ‘polycythemia’, ‘prostate-speciﬁc
antigen (PSA)’, ‘prostate cancer/hypertrophy/benign
prostatic hyperplasia (BPH)’ ‘clinical trial’, ‘randomized
clinical trial’, with any combination of ‘testosterone’,
‘testosterone therapy’, ‘steroid hormone replacement’, or
‘androgen therapy’. The search was limited to trials
performedwithtestosterone,includingtestosteroneesters
and dihydrotestosterone preparations, independently of
delivery. Inclusion criteria for eligible studies were: i) the
use of one active treatment group compared with a
matched placebo or control group, ii) the description of
the time-course of the effect of active treatment, and iii)
randomization, adherence to protocol, and single/double
blinding.Onlyarticlespublishedinpeer-reviewedmedical
journals were used; no abstracts were used.
There is now evidence that the spectrum of
complaints of testosterone deﬁciency cannot be related
to a speciﬁc threshold of testosterone concentrations,
but that thresholds vary with the various symptoms
of testosterone deﬁciency (2). In a cohort of men,
androgen-related loss of libido or vigor became more
prevalent when testosterone concentrations fell below
15 nmol/l, while depression and diabetes mellitus type 2
(also in non-obese men) were signiﬁcantly more present
in men with testosterone concentrations below
10 nmol/l. Symptoms related to androgen deﬁciency
in this study could be subdivided into three independent
groups: psychosomatic complaints, metabolic disorders,
and sexual health problems. Patients suffering from one
of these three groups exhibit distinct features in terms
of androgen levels, age, and body mass index. So,
complaints are not only linked to androgen levels but
age and body mass index carried weight as well in the
manifestation of signs and symptoms of androgen
deﬁciency (2). To further complicate the matter of the
relationship between testosterone levels on the one
hand and symptoms of testosterone deﬁciency on the
other hand, there is the multifactorial impact on certain
androgen-related functions (2). Erectile dysfunction
may serve as an example of a composite dysfunction-
ality in which arterial endothelial function, neuronal
integrity, testosterone concentrations, and psycho-
logical factors play pivotal roles (3, 4),a l m o s t
precluding establishing a straightforward relationship
between testosterone levels and erectile dysfunction.
In a study only testosterone concentrations below
8 nmol/l contributed to the symptom of erectile
dysfunction (2).
Given that the clinical manifestations of
testosterone deﬁciency do not occur at a deﬁnitive
threshold value of circulating testosterone, but vary
with the target organ, associated symptoms and
underlying conditions, it is even more complicated to
establish a time-course since a reversal of these
symptoms of deﬁciency is not only dependent on
restoring serum testosterone to normal. In fact, at
least two new variables are to be entered into the model:
pharmacodynamics of the testosterone preparation and
pharmacogenomics of the treated subject. Indeed, if
replacement therapy fails to restore idiosyncratic
‘adequate’ androgen levels, it also will fail to ‘reverse’
its clinical manifestations. The issue is that deﬁning
‘adequate’ replacement will necessarily have a certain
range of serum testosterone values.
A possible solution to this will be to replace ‘universal
threshold’ with ‘percentage rise’ in circulating testoster-
one achieved under replacement therapy. The latter
varies inversely with the starting concentration of
testosterone and predicts the magnitude and rapidity
of response to treatment. Thus, the less hypogonadal the
subject, the larger the increase in circulating testoster-
one values must be for the effect to be ‘perceived’ by
the subject, and the longer the duration of treatment
to achieve an instrumentally measurable difference in
the desired outcome (5).
The time-course for the spectrum of effects of
testosterone may vary considerably, as testosterone
actions are exerted through a cascade of many different
pathways. Most of the actions of testosterone take place
via the androgen receptor as a transcription factor
activated by testosterone. The bound androgen receptor
acts as transcription regulatory element by binding
to speciﬁc DNA response elements in target gene
promoters, causing activation or repression of tran-
scription and subsequently protein synthesis. Over
the past two decades evidence of rapid responses to
androgens, dependent or independent of the androgen
receptor, occurring at the cellular and organ level
has accumulated. Androgen’s rapid time-course of
action; its effects in the absence or inhibition of the
cellular machinery necessary for transcription/transla-
tion; and in the absence of translocation to the nucleus
suggest a method of androgen action not initially
dependent on genomic mechanisms (6). Examples are
actions of testosterone on the brain and on vascular
tone (7).
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one on androgen-dependent biological variables,
Table 1 presents an indication of quantitative changes
associated with testosterone administration.
Time-course of effects on muscle
mass/strength
In a series of studies, Bhasin et al. (8) have demonstrated
thatupontestosteroneadministration,there isapositive
correlation between blood testosterone concentrations
and leg press strength, thigh, and quadriceps muscle
volume,and,further,levelsofhemoglobinandIGF1.Ina
later study, the same group of authors concluded that
the anabolic response to testosterone can largely be
predicted by the dose administered (9). If the dose
administered is too low, no effects may be demonstrable
(10). Recent studies of the effects of testosterone on
muscle mass/strength are mostly short term. In a study
that combined testosterone with GH, total lean body
mass increased, as did appendicular lean tissue.
Composite maximum voluntary strength of upper and
lower body muscles had increased after 16 weeks (11).
A study investigating the effect of a 12-week long-acting
testosterone administration on maximal exercise
capacity and muscle strength found an increase in
quadriceps isometric strength, maximal voluntary
contraction, and isokinetic strength (peak torque)
(12). Testosterone administration for 20 weeks was
associated with dose-dependent increases in skeletal
muscle mass, leg strength, and power (13). In a study of
180 days of treatment with a 1% testosterone gel
preparation (50 or 100 mg/day, contained in 5 or 10 g
gel), mean muscle strength in the leg press exercise
increased by 90 days and had not improved further at
180 days (14). A study similar in design found an
increaseinleanbodymassandanimprovementof lower
limb muscle strength after 6 months (15). Another
study using high doses of testosterone gel (starting dose
100 mg/day with possible up-titration to 150 mg/day)
observedsigniﬁcantincreasesinlegpressstrength,chest
press strength, and stair climbing power with a load
within 6 months (16). A study administering testoster-
one enanthate, 200 mg/2 weeks observed major effects
to occur over the ﬁrst 12 months of testosterone
administration, thereafter minor increases could be
observed (17). It can be concluded that the effects of
testosterone on muscle strength are demonstrable after
12–20 weeks and that depending on the achieved
testosterone levels, the maximum effects are attained
after6or12months.ThedataaresummarizedinFig.1.
Time-course of effects on bone mineral
density
The effects of testosterone on bone mineral density are
in part mediated by estrogens, derived from testosterone
via aromatization (18). Testosterone improves bone
mineral density at the lumbar spine compared with
placebo, but at the femoral neck improvements are less
certain (19). Testosterone produces a consistent
reduction in bone resorption markers (20). Effects on
bone mineral density have been shown in studies of 6
months duration (21, 22), 8 months duration (23),o r1
year duration (24). From studies analyzing the effects of
testosterone administration over as long as 36 months
(25, 26) an increase was observed over that time period
and it did not become clear whether the maximum
effects of testosterone improving bone mineral have
been attained after 36 months. The data are sum-
marized in Fig. 1.
Table 1 Observed mean range of changes in selected measurable
outcomes of testosterone administration to hypogonadal men in
reviewed studies.
Outcome Values (range) References
Muscle mass (kg) 0.4 to 16.4 (11–14, 17, 18, 20, 24)
Strength (1 repetition max) (11–20)
Leg press strength (kg) 11.6 to 76.5
Composite strength (%) 14 to 35
Isokinetic power torque (Nm) 4.7 to 9.6
Handgrip (kg) 3.5 to 5.3
Bone mineral density (24, 25, 27–29, 94)
Femoral neck (g/cm
2) 0.01 to 0.03
Lumbar spine
g/cm
2 0.04 to 0.1
(%) 5 to 8.6
Body composition (17, 20, 33, 35, 37)
Total mass (kg) K3.2 to 1.69
Fat mass (kg) K0.4 to K5.7
Effects on lipids (mmol/l) (38–41, 43–47, 55)
Total cholesterol K0.4 to K0.23
Triglycerides K0.98 to 0.1
HDL cholesterol K0.05 to 0.692
LDL cholesterol K0.39 to K0.05
Glycemic control (34, 39, 43, 46, 49–51,
53–55)
Glucose (mmol/l) K0.22 to K6.5
Insulin (mIU/l) K0.5 to K14.0
HOMA index K0.72 to K4.2
HbA1c (%) K0.2 to K6.3
Cardiovascular effects (mmHg) (25, 38, 44, 47, 62, 64,
69)
Systolic BP K0.5 to K7
Diastolic BP K0.5 to K7
Pulse pressure K1.9 to K2.6
Pulse wave velocity 0.2 to K0.7
Augmentation index K1.2 to K4.3
Flow mediated dilatation (%) 1.8 to 2.6
Inﬂammatory markers (pg/dl) (35, 42, 46, 50, 68, 69)
IL6 K0.02 to 1.6
IL1b K0.2
IL10 K0.15
hs-CRP K0.43 to K1.1
TNF-a (mg/dl) 6.1 to K3.1
Effects on erythropoiesis (17, 38, 43, 89, 90)
Hematocrit (%) 1.0 to 6.5
Hemoglobin (g/dl) 0.5 to 3.5
Effects on prostate (43, 46, 47, 91–93, 95)
PSA (ng/ml) K0.2 to 0.8
Prostate volume (cm
3) 0 to 10.1
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Testosterone plays a signiﬁcant role in obesity, glucose
homeostasis, and lipid metabolism (27). At the cellular
level there is now insight into the effects of androgen
deprivation/administration on fat and muscle mass.
Testosterone regulates lineage determination in
mesenchymal pluripotent cells by promoting their
commitment to the myogenic lineage and inhibiting
their differentiation into the adipogenic lineage through
an androgen receptor-mediated pathway. The obser-
vation that differentiation of pluripotent cells is andro-
gen dependent provides a unifying explanation for the
reciprocal effectsofandrogens onmuscle and fatmassin
men (28, 29). Upon testosterone administration there is
a decrease in fat mass and an increase in lean body mass
andthenetresultisoften,butnotalways,thattotalbody
weight does not show major changes. An increase in
total mass was found after 3 months (14) and an
increase in weight in elderly men after 3 months (30).A
decrease in weight has been observed after 3 months
(31) and 6 months (17), with further progressive
decrease over 24 months (32). An increase in total
body mass, lean body mass, and a decrease in fat mass
were found after 3 months (14, 30) or 6 months (17).A
decrease in fat mass has been widely reported after 3
months (14,30, 31) or6months (17),and a decreasein
percent fat mass equally after 3 months (14, 31).
It is now commonly accepted that a preferential
accumulation of fat in the abdominal region is
associated with an increased risk of type 2 diabetes
mellitus and cardiovascular disease, not only in obese
subjects but even in non-obese subjects (33). Therefore,
the effects on trunk fat, often measured as changes in
waist circumference (34), are very relevant effects of
testosterone treatment. A decrease in trunk fat or waist
circumference was noted in a number of studies after 3
months (35, 36) with continuous decline over 24
months (32) and a decrease in the waist hip ratio
after 3 months (31, 36) or after 6 months and 30 weeks
respectively (17). A continued decline up to 110 weeks
was reported (37). Body mass index as a widely used
measure of body composition declined after 6 months
with further improvement during an observation period
of 2 years (32). The data are summarized in Fig. 1.
Time-course of effects on lipids
Decreases in serum total cholesterol have been noted as
quick as after 4 weeks (38, 39) but most studies have
reported a decrease after 3 months (35, 36). A decrease
after 24 weeks was observed in a recent study (40),
others have found this to occur after 9 months (41) or
12 months (42) with a maximum reached after 12
months (32).
The decrease in serum triglycerides follows a similar
pattern:after4 weeks(38), after 3 months (35),a n dw i t h
further decrease over 9 months (41) or 12 months (43).
The decrease in low-density lipoprotein cholesterol
seems somewhat slower: after 3 months (35), after
40–44 weeks, (44) or after 12 months (42) with a
maximum observed after 24 months (32).
Studies have found both an increase and decrease in
high-density lipoprotein cholesterol. An increase was
found to occur after 3 months increasing further during
12 months (43), after 6 months, (35) or close to 1 year
(44). Continuous increase was observed over 24
months (32). The data are summarized in Fig. 2.
Time-course of effects on glycemic
control
Several studies indicate that upon testosterone admin-
istration, serum glucose is reduced after 3 months in
men with impaired glucose tolerance (31, 36, 43).I na
recent study, this was observed after 24 weeks only in
men with baseline glucose O110 ng/ml (6.6 mmol/l)
36 months
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Figure 1 Time-course on body composition and strength.
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Figure 2 Time-course on lipids.
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levels were !110 ng/ml (6.6 mmol/l) (40). An early
study reported a decrease in glucose and glucose
disposal rate after 9 months (41).
A decrease in serum proinsulin and insulin was noted
after 3 months (43) or 6 months (45), and a decrease in
homeostasis model assessment index of insulin resistance
(HOMA-IR) after 3 months (36) or 6 months (45–47).
A decline in HbA1c was observed after 3 months (31,
36, 43) with further decrease after 12 months (43).
Low serum testosterone levels are associated with an
adverse metabolic proﬁle which may be explained by the
observation that low testosterone levels and impaired
mitochondrial function promote insulin resistance in
men (48). And indeed, in an experimental study,
stimulation of endogenous testosterone was shown to
increase insulin sensitivity within 48 h (49).
Recently, it has been demonstrated that the interplay
between insulin sensitivity, triglyceride levels, and
androgens is practically immediate, as it occurs within
a week, and is not facilitated by changes in body
composition alone. Concomitantly increasing testoster-
one and decreasing estradiol (E2) levels had positive
effects on both postprandial triglyceride handling and
insulin sensitivity in elaborate clamp models during
manipulation of these serum sex steroid levels (50). The
effects on postprandial triglyceride handling can there-
fore be observed in line with previous results and seem
to be of relevance for metabolic risk (51, 52).A n
improvement in insulin sensitivity upon testosterone
administration resulted in reduced fasting glucose and
insulin levels within a single week (50), corroborating
the former reports about an increase in insulin
sensitivity upon stimulation of endogenous testosterone
within 48 h (49) and an acute reduction in insulin
sensitivity 2 weeks after discontinuing testosterone
replacement in severely hypogonadal men (53).
Such observations are most likely attributed to
testosterone-induced changes in lipid metabolism
and/or altered postreceptor insulin signaling in muscle
(54) and also improved insulin sensitivity enhancing
muscle lipid uptake (55). Furthermore, the aforemen-
tioned intervention increased the response of post-
prandial glucose-dependent insulinotropic polypeptide
(GIP) release (50). Effects of sex steroids on GIP had not
been reported before.This is of speciﬁc interest, as action
of GIP is not limited to pancreatic cells and may affect
lipid homeostasis (56) and intestinal glucose transport
(57). The data are summarized in Fig. 3.
Time-course of effects on blood pressure
and other cardiovascular effects
In some studies a decline in diastolic blood pressure has
been observed, after 3–9 months (22, 35, 41, 44) and in
some studies in systolic blood pressure also (35, 44).
Maximum effects were observed after 12 months (35).
Adecreaseintherestingheartrateoccurredafter40–44
weeks (44). A decrease in arterial stiffness measured as
pulse wave velocity was measurable after 48 h (58) and
in large artery compliance after 3 months (58). Several
studies have been conducted in men with heart disease.
In men with chronic stable angina pectoris the increase
in time to 1 mm ST segment depression was noticeable
after 14 weeks (59). The ischemic threshold had
increased after 4 weeks (38). Exercise capacity in men
with chronicheartfailure increasedafter12weeks(60),
whereas the cardiac index (cardiac output related to
body surface) had already increased after 180 min.
In men with coronary artery disease ﬂow-mediated
vasodilatation was observed after 12 weeks (61).
Time-course of effects on inﬂammatory
factors/endothelial markers
Lowsexhormonelevelsareassociatedwithinﬂammation
(62).Alreadyafter3weeksoftestosteroneadministration,
a decline wasnotedinIL6 (63)and inanother studyafter
16weeks(64).AdecreaseinC-reactiveprotein(CRP)was
observed after 3 weeks (63) and in other studies after
3 months (32, 43).I nas t u d yi np a t i e n t sw i t hC r o h n ’ s
disease, CRP levels continued to decline over 24 months
(65). A decrease in tumor necrosis factor a and in
interleukin 1b was noted after 4 weeks (39). Asymmetric
dimethylarginineisanendogenousNOsynthaseinhibitor
and appears to decline upon testosterone administration
after 10 days (66) or after 4 weeks (67).
Time-course of effects on sexual
parameters
Effects on libido
Effects on libido, sexual desire, sexual thoughts and
fantasies and satisfaction with sexual life manifest
themselves rather rapidly: after 3 weeks (68) or
30 days (14). Some studies have measured these effects
only after 3 months (31).
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Figure 3 Time-course on glucose and insulin.
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Effects on erection also appear rather rapidly: after 3
weeks (68). Increase in morning erections occur after 3
weeks (68). An increase in percentage of full erections
and sexual performance and satisfaction with erections
was noticed after 30 days (14, 69), an increase of
ejaculations and sexual activityafter 2 weeks (70) and 3
weeks respectively (68). In patients with veno-occlusive
dysfunction, testosterone undecanoate restored erectile
function after a minimum of 3 months and a maximum
of 11.5 months (71).
The International Index of Erectile Function is a
reliable, self-administered measure of erectile function
that is cross-culturally valid and psychometrically
sound, with the sensitivity and speciﬁcity for detecting
treatment-related changes in patients with erectile
dysfunction. It has ﬁve domains: erectile function,
orgasmic function, sexual desire, intercourse satis-
faction, and overall satisfaction. Increases in the
IIEF erectile function have been noted after 3 months
(35, 40) but increases in IIEF sexual desire, intercourse
satisfaction, and overall satisfaction appear already
after 6 weeks (40). Maximal effects are usually achieved
after 3–6 months (72) but may take even up to 1 year
in individual cases (71). The data are summarized
in Fig. 4.
Time-course of effects on quality of life
The St Louis University Androgen Deﬁciency in Aging
Male (ADAM) is a screening tool for hypogonadism in
older males. An improvement was noted after 1 month
of testosterone treatment (38).T h eA g i n gM a l e s ’
Symptom (AMS) questionnaire is a 17-item scale
assessing health-related quality of life and symptoms in
aging men (e.g. somato-vegetative, psychological, and
sexual symptoms) (73). Improvements on scores on the
AMS have been noted after 1 month (38), 6 weeks (40)
to 3 months on treatment with parenteral testosterone
undecanoate (35) or after 9 months on testosterone gel
(74) continuing over a total of 18 months (74).
Time-course of effects on psychological
variables
Several studies report an improvement in depression
after 3 weeks (68) or 1 month (38). Increase in good
mood and a decrease in bad mood were noted after
3 weeks (68) or after 30 days (14). There was also
an increase in motivation after 30 days which was
maintained thereafter (14). Two studies using the
Hamilton Depression Rating Scale found an improve-
ment in depression after 6 weeks (75) or 8 weeks (76).
A number of psychological variables (increase in
sociability, decrease in anxiety, increase in concen-
tration, and self-conﬁdence) were apparent after 3
weeks (68). A decrease in fatigue and listlessness was
found after 1 month (31) or 6 weeks (68). A transient
increase in anger/hostility was found in eugonadal
men whose testosterone levels were raised above
normal after 2 weeks (77).
In a larger set of severely depressed men (nZ2!50),
effects of testosterone replacement therapy (TRT) by gel
versus placebo were observed within 6 weeks. The effect
was not consistent within the whole group of patients.
It is likely that, in severe clinical depression, the
receptiveness for testosterone effects depends on the
overall pattern of disturbed neurotransmitters,
especially noradrenaline and serotonin, and also base-
line testosterone concentrations (78). It is very likely
that the positive effects of testosterone on depressive
symptoms start as early as after 3–6 weeks, but will
most likely take 18–30 weeks to ﬁnd the patient with a
signiﬁcant improvement. A recent study in hypogona-
dal men receiving i.m. testosterone undecanoate
demonstrated such effects. It is remarkable that effects
were more pronounced in men with the lowest baseline
testosterone levels (79).
Similarly, effects of testosterone administration in
hypogonadal men on the ability to process spatial data
of visual content were observed within 2 weeks of
treatment (80). These effects are obviously directly
related to testosterone and not its aromatization
product E2, as it was later conﬁrmed in a placebo-
controlled trial involving an aromatase inhibitor
combined with testosterone administration in hypogo-
nadal men. These patients exhibited a markedly
improved spatial working memory within 3 weeks,
improving further until week six (81).
Time-course of effects on erythropoiesis
The effects of testosterone on red blood cell formation
(hemoglobin and hematocrit) are dose dependent
Number of erections per week
Morning erections
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Time of maximum effect
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Figure 4 Time-course on sexual parameters.
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effects are apparent after 3 months (14, 35, 40) and a
maximum is reached after 9–12 months (35). The data
are summarized in Fig. 5.
Time-course of effects on the prostate
In hypogonadal men treated with testosterone, levels of
PSA rise usually up to levels of eugonadal men (84).
Upon judging the time-course of effects of testosterone
on the prostate, it is of note that aging itself is a factor
in the rise of both prostate volume and PSA (84), and
there is no endpoint in the effects of testosterone on
the prostate. A rise in PSA levels was noticed after
6 months, whereafter over the following 24 months
there was no signiﬁcant further increase (85). Other
studies have found a rise of PSA levels after 3 months
(40), some only after 12 months (43). An increase in
prostate volume was noted after 3 months (86) and
after 12 months (44). One study over 24 months found
no signiﬁcant increase in both PSA and prostate
volume. In a study of 123 subjects over 42 months of
testosterone gel application, there was signiﬁcant
increase in serum PSA over the ﬁrst 6 months and
then no further signiﬁcant increases with continued
testosterone treatment was found (87). In a study of 81
hypogonadal men (mean age 56.8 years) followed for a
mean (range) of 33.8 (6–144) months PSA levels did
not increase signiﬁcantly at 1-year intervals for 5 years
(88). The data are summarized in Fig. 5.
Discussion
This is a systematic analysis of the time-course of the
spectrum of biological effects of testosterone on the
various target systems. The authors view this as a
worthwhile endeavor for a number of reasons. Attend-
ing physicians can prepare their patients for the
intervening time periods before effects of testosterone
can be experienced. Studies investigating the effects of
testosterone have to take this time-course into consider-
ation to design the duration of studies to be able to have
quantiﬁable measurements.
It is of note that almost none of the quoted studies had
been speciﬁcally designed to assess the time-course of
effects. Some studies measure effects of testosterone only
after 3 months (31), and, particularly, effects on libido
and erections have occurred well before this time span
(14, 68).
We noticed considerable differences in the occurrence
of effects of testosterone. Effects on libido and other
psychological variables and effects on vasculature occur
rather rapidly. It may well be that these effects are not
mediated via the classical androgen receptor but
through other mechanisms like effects on membranes
(6, 7). Also effects on erection occur rather rapidly and
may be partially explained by non-genomic effects on
vascular penile erectile tissue (89).
The effects of testosterone on glycemic control and
variables clustered in the metabolic syndrome occur
somewhat slower, but there is evidence that acute
testosterone fall during deprivation therapy is directly
related to a worsening in insulin sensitivity (53).
However, in a recent study, the authors were not
able to substantiate their earlier ﬁnding (90) and
hypothesize insulin resistance associated with chronic
low testosterone levels may be largely driven by
decreased fat-free mass, increased percent body fat,
and/or other metabolic regulatory factors. This may
also apply to other factors of the metabolic syndrome.
Testosterone inhibits the expression of the activity of
lipoprotein lipase, the main enzymatic regulator of
triglyceride uptake in the fat cell, preferentially in
abdominal fat (28, 29). Several studies have indeed
conﬁrmed that testosterone treatment reduces waist
circumference which, in its simplicity, appears to be a
valid parameter of the degree of visceral obesity (91).I n
our own studies, signs and symptoms of the metabolic
syndrome improved substantially following adminis-
tration of long-acting testosterone undecanoate (32,
35, 92) and improvements in glycemic control and
lipids parallel improvements in body composition.
The effects of testosterone on muscle and bone involve
protein synthesis and are a result of genomic actions of
testosterone and, therefore, rather slow.
Apart from reviewing the onset of effects of
testosterone treatment in hypogonadal men, it would
also be possible to look at the onset of symptoms of
testosterone deﬁciency in patients on androgen depri-
vation therapy (ADT), standard treatment for men with
advanced prostate cancer. ADT causes unfavorable
changes in body composition, insulin resistance and
other risk factors for cardiometabolic diseases leading to
an increased incidence of cardiovascular diseases and
type 2 diabetes (for review (93, 94)). However,
deprivation of testosterone and the time-dependent
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testosterone action in testosterone treatment, even in
the same parameter. Therefore, it was decided to restrict
this paper to aspects of testosterone treatment.
Finally, in the present analysis it was attempted to
select those studies of testosterone treatment that
provided adequate doses/delivery of testosterone. It is
obvious that sub-optimal therapeutic regimens or,
alternatively, inappropriate patient selection (eugonadal
or men with biochemical but not clinical hypogonad-
ism) may show different time-course of effects.
In conclusion, this analysis tries to chart the
differences in time periods after which biological effects
of testosterone administration in hypogonadal men
occur. This may add to a better understanding of the
physiology of androgen action. Earlier studies have
shown that there are thresholds for the various actions
testosterone: in other words signs and symptoms of
testosterone deﬁciency appear at different threshold
values of circulating testosterone. The above results call
for a well-designed study that charts the time required
to restore an androgen-dependent function with the
optimal circulating testosterone for that speciﬁc andro-
gen-dependent function. These studies are not easy to
perform. Ideally, they should measure at what serum
levels of testosterone, all androgen-dependent biological
functions are restored. Some biological functions, like
erectile functions are composite in nature, and next to
testosterone, endothelial function and psychological
factors are equally relevant (2). A major problem is the
so-called late onset hypogonadism: the decline in serum
testosterone with aging. It is still hotly debated whether
this is a true form of hypogonadism, or a decline of
serum testosterone associated with the progressive
accumulation of health problems with aging (95, 96),
but rather independently of the process of aging itself.
Though small-scale studies show beneﬁts and accep-
table risks of treating elderly men with lower than
normal testosterone levels (46, 97), a verdict can only
be reached with large-scale studies including 5000 men
over 5 years (95), for which presently the funding is not
available. There is a degree of consensus that elderly
men with serum testosterone clearly below the
reference ranges and persistent clear clinical signs of
hypogonadism may justiﬁably be treated (98, 99), but
there remains a large degree of dissent.
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